U.S. Health Officials Push Policy to Let Specialty Pharmacies Make Certain Peptide Injections

The Department of Health and Human Services has submitted an interim access policy for peptides to the White House, where it will be reviewed by the Office of Management and Budget.

The proposal would allow specialty pharmacies to compound specific peptide injections, a class of compounds that have largely escaped FDA regulation.

Peptides are basic protein components used in hormones and have approved medical uses such as diabetes and weight‑loss treatments, but the peptides targeted by the plan have not undergone the usual approval process.

Advocates, including Health Secretary Robert F. Kennedy Jr., say the change will expand access for consumers seeking benefits like increased muscle mass, anti‑aging effects, or more energy, despite the lack of formal approval.

HHS officials have not provided further comment, and the policy’s economic impact will be examined by the Office of Management and Budget.